
Editor's Note: At the 2026 European Society for Medical Oncology (ESMO) Congress, Professor Lei Fan of Fudan University Shanghai Cancer Center presented results from the SWITCH platform study. This prospective, open-label, Phase II platform study was designed to investigate the efficacy and safety of sequential treatment with novel ADCs targeting different antigens in patients with HER2-negative metastatic breast cancer whose disease had progressed following prior antibody-drug conjugate (ADC) therapy. Following the presentation, Oncology Frontier invited Professor Lei Fan to discuss the rationale and design of the SWITCH study, its key findings, and the implications for future ADC sequencing strategies and drug development.
01
Oncology Frontier: You presented data and results from the SWITCH study at this year’s ESMO Congress. Could you briefly introduce the rationale behind the study design? The results showed that confirmed objective response rates (ORRs) were relatively limited across all cohorts, with responses observed only in patients who switched from disitamab vedotin (RC48) to a TOP1 inhibitor-based ADC. How do you interpret these findings? Do they suggest that payload cross-resistance, rather than the target antigen itself, is a major driver of ADC resistance?
Professor Lei Fan: On the morning of October 26, during the Rapid Oral 2 session on breast cancer, I presented results from a platform study called SWITCH, led by Professor Zhi-Ming Shao at our center.
As we all know, ADCs have profoundly reshaped the treatment landscape of advanced breast cancer and are now moving into earlier disease settings. At this year’s ESMO Congress, several novel ADCs also reported breakthrough data. However, one key question remains: What should we do after resistance to an ADC develops? At present, the optimal treatment sequence following ADC resistance has yet to be established. As its name suggests, the SWITCH study aims to explore how treatment strategies can be switched after ADC resistance.
The results presented this time represent the first step, or initial version, of the study. In this version, we evaluated four novel ADCs with different targets: Cohort A, SHR-A1811; Cohort B, SHR-A1921; Cohort C, SHR-A2009; and Cohort D, SHR-A2102. All four ADCs use a TOP1 inhibitor payload. The objective was to determine whether switching to a novel ADC with a different target could still offer meaningful efficacy and safety after resistance to an earlier TOP1 inhibitor-based ADC.
Regarding the primary endpoint, ORRs were very low among patients previously treated with TOP1 inhibitor-based ADCs who switched to ADCs targeting different antigens. The ORRs in Cohorts A, B, C, and D were 0%, 8.3%, 0%, and 5%, respectively. None met the prespecified threshold. These findings indicate that, after resistance to a TOP1 inhibitor-based ADC, switching to an ADC with a new target but the same TOP1 inhibitor payload is not a feasible strategy.
Another noteworthy finding was that, among the 54 patients enrolled in this study, three had previously received RC48, a microtubule inhibitor-based ADC with an MMAE payload. Two of these three patients achieved a favorable response after switching to a TOP1 inhibitor-based ADC. Given the very small sample size, we cannot draw a definitive conclusion that changing the payload will necessarily produce superior outcomes. Nevertheless, this observation points toward a potential direction for future treatment strategies: rather than changing the target, we may need to consider changing the payload.
As for the secondary endpoints, median progression-free survival (mPFS) was generally short across the cohorts, ranging from 1.4 to 3.0 months. Consistent with the ORR findings, patients previously treated with the microtubule inhibitor-based ADC RC48 showed numerically longer PFS when receiving a second ADC. This also suggests that, for patients with primary resistance to a target, switching to an ADC against the same target but with a different payload may be an appropriate strategy. In contrast, among patients who had achieved a very long PFS with their first TOP1 inhibitor-based ADC, PFS was generally less than three months after switching to another ADC. This further raises the possibility of acquired payload resistance.
Therefore, in future expansion studies, we need to distinguish more precisely between populations with primary resistance to the target and those with secondary resistance to the payload. This distinction could provide important guidance for developing future sequencing strategies.
02
Oncology Frontier: Based on the SWITCH study’s key finding that payload cross-resistance may be a major driver of ADC resistance, what implications do you think this has for developing future ADC sequencing strategies and guiding the development of novel ADCs?
Professor Lei Fan: This is an excellent question. From a mechanistic perspective, there is a general understanding that switching from one TOP1 inhibitor-based ADC to another ADC carrying a TOP1 inhibitor payload after resistance has developed is unlikely to produce a favorable treatment outcome. This trend has also been borne out in our clinical practice.
Currently, most ADCs use TOP1 inhibitors as their primary payloads. In addition, previous clinical trials have often excluded patients who had already received TOP1 inhibitor-based ADCs. Therefore, I believe future drug development strategies, including those pursued by pharmaceutical companies and investigators, should place greater emphasis on ADCs with payloads that have the potential to avoid cross-resistance. Examples include MMAE and eribulin, which are microtubule inhibitor-based payloads.
Of course, we should not limit our focus to switching from one ADC to another after ADC resistance develops. Other treatment approaches remain viable, and we should not overlook the role of chemotherapy in this setting. In the subsequent plans for the SWITCH platform study, we may explore three different strategies: first, payload switching, involving a change to an ADC with a different payload; second, switching to chemotherapy; and third, combination strategies, in which a novel ADC or chemotherapy is combined with a potential therapeutic target, including immunotherapy, anti-angiogenic targeted therapy, and existing bispecific antibodies, with the aim of achieving better outcomes for patients.
